RxDoctor Payments Data

Zhenhui Li, MD

Neurology · York, PANPI 1184694374

Payments from drug & device makers

$2,861in general payments, 2019–2025

Across 108 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$450
  • Lundbeck LLC$162
  • Genentech USA, Inc.$126
  • Teva Pharmaceuticals USA, Inc.$124
  • AstraZeneca$116
  • plus $439 from 9 others

What the payments were for

  • Consulting fees$45016%
  • Food & beverage$2,32481%
  • Education$873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,861 in reported general payments places this provider in the 60th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$110,447
Medicare patients
527
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe128$91,859
BotoxOnabotulinumtoxina39$61,276
Glatiramer Acetate13$32,716
BriviactBrivaracetam13$17,865
QuliptaAtogepant16$16,689
Nurtec OdtRimegepant Sulfate11$11,445
Emgality PenGalcanezumab-Gnlm17$11,290
ExelonRivastigmine12$9,836
Memantine Hcl372$9,545
Rivastigmine49$8,487
Gabapentin473$7,710
Carbidopa-LevodopaCarbidopa/Levodopa361$7,321
Levetiracetam214$5,580
Donepezil Hcl403$3,907
Carbidopa-Levodopa ErCarbidopa/Levodopa65$3,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta$1,444$77,96555 claims
UCB, Inc.Briviact$84$17,86513 claims
PfizerNurtec Odt$32$11,44511 claims
NovartisExelon$94$9,83612 claims
Lilly USA, LLCOlanzapine$93$57428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 941 neurology providers in Pennsylvania.

Other neurology in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →